Pharmaco

Manufacturing

The company has three dedicated state-of-the-art production facilities located in Athens (Greece), designed in accordance with EU cGMP requirements.

Oncology Sterile Liquid Dosage Forms (inaugurated in 2006)

  • Product Form: water-based solutions
  • Molecules handled: Carboplatin, Doxorubicin, Epirubicin, Mitoxantrone, Oxaliplatin & Clofarabine
  • Compounding Capacity: up to 100L
  • Primary Packaging: glass vials with rubber stopper and flip-off cap
  • Vials Filling Volume: ranging 5ml - 100ml
  • Technology: cleanroom, isolator, aseptic filling, terminal sterilization
  • Full Capacity: 5 million vials
  • Accreditations: EU GMP, Gulf Countries Council (GCC), Health Canada, Therapeutic Goods Administration (TGA-Australia)

 

Oncology Oral Solid Dosage Forms (inaugurated in 2007)

  • Product Forms: tablets (uncoated or coated) & hard gelatin capsules
  • Molecules handled: Anastrozole, Bicalutamide, Exemestane, Finasteride, Flutamide, Hydroxyurea, Letrozole, Tamoxifen & Thioguanine
  • Granulation Capacity: up to 150kg
  • Primary Packaging: blistersv
  • Full Capacity: 230 million tablets, 75 million capsules
  • Accreditations: EU GMP, Gulf Countries Council (GCC), Health Canada, Therapeutic Goods Administration (TGA-Australia)

 

Conventional Solid Dosage Forms (renovated in 2005)

  • Product Forms: tablets (uncoated, coated, orodispersible and chewable), hard gelatin capsules, oral solutions & nasal sprays
  • Molecules handled: more than 55
  • Primary Packaging: blisters & plastic bottles (for solid dosage forms)
  • Full Capacity: 780 million tablets, 260 million capsules, 7,5 million glass vials, 3,7 million plastic bottles
  • Accreditations: EU GMP, Gulf Countries Council (GCC), Health Canada, Therapeutic Goods Administration (TGA-Australia)

 

Accreditations

  • ISO 9001
  • EU GMP
  • GCC GMP
  • Health Canada
  • TGA
    (Australian Health Authorities)
  • Taiwan GMP
  • Korea Ministry of Health